The latest updates on Ozempic, Mounjaro, Wegovy and GLP-1 treatments
Ozempic afeta a função renal? Veja o que o SUSTAIN-6 e o estudo FLOW mediram, o que ainda não sabemos e o que perguntar ao médico.
Thinking about a GLP-1 pen switch? Here are the signs that often start that conversation, and what to bring to your doctor.
A once-weekly pen that combines insulin icodec and semaglutide is getting attention in Brazil. Here's what it contains and what ANVISA registration does, and doesn't, change for people with type 2 diabetes.
New research on semaglutide and shedding raises questions, but the answers are still partial. Here's how to read the evidence and what to ask your doctor.
Brazilian labs are reportedly gaining ground in semaglutide sales. Here is what that share does and doesn't tell you, and how to check the product in your hand.
Retatrutide is being called 'stronger than Mounjaro' in headlines. Here's what the trials measured, where the comparison breaks down, and what to check in Brazil.
ANVISA opened an investigation into 13 reported cases of NAION optic nerve disease in GLP-1 medication users. Here's what the current evidence shows and what patients should know.
Research is uncovering a surprising connection between your gut bacteria and how well GLP-1 medications like semaglutide work for weight loss. Here's what the science says.
Curious about what happens after reaching your weight loss goal on Ozempic? Here's what the maintenance phase really involves and what the research shows about long-term outcomes.
Brazilian customs and health authorities have intensified seizures of irregular weight loss medications at major entry points. Here's what consumers need to know about the findings and the risks involved.
Answer a few quick questions and get tailored guidance for your treatment.
or download the app
